Berkeley Pharma Tech
Journal of Medicine

Exploring the Intricacies of Neuroinvasive Infections: A Comprehensive Analysis of SARS-CoV-2's Impact on the Nervous System

By: Fantasia Obomanu, Emily Woo, Sunanya Adoni, Verdasri Surada

Correspondence:
ftobomanu@uchicago.edu



Keywords:
Neuroinvasive infections
SARS-CoV-2
Central Nervous System (CNS)
Neurological complications
Viral pathogenesis

Submitted December 13, 2023
Accepted August 19, 2024
Published December 27, 2024

Full Open Access

Abstract

Infectious diseases have had significant threats to human health, with neurological complications as a challenging frontier in the realm of medical science. Neuroinvasive infections are caused by viruses, bacteria, fungi, or protozoa and can lead to various neurological problems such as meningitis, encephalitis, abscesses, myelitis, and neuromuscular dysfunction. Among these pathogens, viruses, including Dengue, West Nile, and most recently SARS-CoV-2, have emerged as potent human pathogens capable of inflicting severe damage to the central nervous system (CNS), culminating in hemorrhagic diseases.

1. Introduction

1.1 The Multifaceted World of Neuroinvasive Infections

The pathogenesis of neuroinvasive infections is characterized by the remarkable ability of these pathogens to infiltrate the nervous system. They exploit a mechanism known as axonal transport, which utilizes the physical structures of axons– the elongated projections of nerve cells—to move within the host (infected person). By doing so, they evade immune responses focused on targeting them in other parts of the body. The inflammatory responses triggered by these infections resemble those observed autoimmune disorders, involving microglial proliferation (responses of immune cells in the brain), blood-brain barrier dysfunction (a protective barrier in the brain), and immune cell infiltration.

The intricate interplay between pathogens, the nervous system, and the resulting neurological consequences forms the core of our exploration.The intricacy lies in the multifaceted ways these pathogens can engage with the nervous system, potentially leading to a spectrum of neurological consequences. This dynamic relationship is not a unidirectional process; rather, it involves a reciprocal influence where the pathogen can impact the nervous system, and vice versa. Understanding this intricate interplay is crucial for researchers delving into the mechanisms of neuroinvasion and subsequent neurological manifestations.

The COVID-19 pandemic serves as a great example, illustrating the practical implications of the complex relationship between pathogens and the nervous system. SARS-CoV-2, the virus responsible for COVID-19, has not only demonstrated the ability to infect respiratory cells but has also revealed a neurotropic potential. The virus can enter the central nervous system, leading to a range of neurological complications, from mild symptoms like loss of smell to more severe conditions such as encephalitis. This manifestation underscores the intricate nature of the interplay between pathogens and the nervous system. The unprecedented scale and global impact of the COVID-19 pandemic further emphasize the urgency of

comprehending these complex interactions for effective medical research and intervention.

In tandem with these neuroinvasive infections, the COVID-19 pandemic has presented a global health crisis of unprecedented proportions. The novel coronavirus, SARS-CoV-2, has unveiled the complex landscape of neurological complications, thrusting the nervous system into the forefront of medical research.



Figure 1. Model of External Transport and Neuron-Neuron or Neuron Non-Neuron Cells Propagation. (A) Murine primary mixed neuron cultures (PMNC) grown in Xonachip microfluidic compartmentalized chambers. These devices allow fluidic isolation of axons. (B) Electron microscopy images of infected PMNC (C) Model of HCoV□OC-43 propagation

1.2 Purpose of the Review

The purpose of this review is to investigate the potential therapeutic interventions aimed at mitigating the neurological damage inflicted by the SARS-CoV-2 pathogen, with a particular focus on the prevention of neurological consequences resulting from an infected host. The evolving landscape of neuroinvasive infections and the continuous battle against the repercussions of SARS-CoV-2 on the nervous system beckon us to chart a course toward effective therapeutic strategies that can offer relief and hope to those suffering from the consequences of COVID-19.

2. Significance of the Global Impact & Damage of SARS-CoV-2

The global impact of SARS-CoV-2 has been staggering, with approximately 600 million people affected by COVID-19 as of 2022.[1] SARS-CoV-2, akin to neuroinvasive infections, can cause a wide array of neurological problems. These problems include anosmia, ageusia, headaches, confusion, delirium, strokes, encephalitis, Guillain-Barre syndrome, and ischemic stroke.[2] This disease affects multiple organs and systems in the body, leading to severe and long-term complications.[3]

The mechanism through which SARS-CoV-2 gains access to the central nervous system (CNS) is a subject of ongoing investigation. It is suggested that the virus may exploit multiple routes, including crossing the protective blood-brain barrier (BBB) or interacting with the ACE2 receptor, which is expressed in the brain. The direct assault of SARS-CoV-2 on the CNS, coupled with the abnormal immune response within the CNS, contributes to the complex nature of the disease.

Beyond its respiratory manifestations, COVID-19 has revealed its capacity to inflict neurological deficits at different stages of the infection. Neurological deficits associated with COVID-19 include headache, changes in sense of smell and taste, muscle pain, mood disturbance (depression, anxiety), weakness of the limbs, loss of consciousness, seizure, confusion, vision changes, acute encephalopathy, cerebrovascular events, acute inflammatory syndromes, and seizures. These deficits can occur in both adults and preterm infants with low birth weight born to COVID-19 affected mothers. Neurological sequelae after critical COVID-19 disease can result in substantial deficits in activities of daily living and reduced health-related quality of life. Moreover, it can leave a lasting imprint on the nervous system, causing post-infectious complications and long-term effects that are yet to be fully understood.

The emergence of SARS-CoV-2 variants, characterized by their high mutation rates, has posed further challenges to global health. The diversity

in the presentation of COVID-19 symptoms, coupled with the complexities of diagnosing the disease, has added layers of difficulty to its management.[4]

3. Neurological Damage Caused by SARS-CoV-2

The evidence of neurological damage caused by SARS-CoV-2 is becoming increasingly clear, as various studies have uncovered potential mechanisms underlying this damage. Autopsy analyses of COVID-19 patients, observed using electron microscopy and fluorescence microscopy, have shown the presence of SARS-CoV-2 proteins in vital organs, including the brain, indicating the potential for neuroinvasion.[5,6] Additionally, the isolation of SARS-CoV-2 from the cerebrospinal fluid (CSF) in some patients further supports the notion of neuroinvasion.[7] Furthermore, numerous COVID-19 patients have reported anosmia (loss of smell) and various other neurological symptoms, highlighting the neurological impact of the virus.[8,9] Studies using human brain organoids have revealed clear evidence of SARS-CoV-2 infection in cortical neurons, accompanied by metabolic changes in infected and neighboring neurons.[10] These studies have also found the presence of ischemic damage and microinfarcts in post mortem brain samples of COVID-19 patients, indicating the potential for severe neurological consequences.[11] In in-vivo studies using mice, similar to previous reports of SARS-CoV, researchers observed increasing viral titers in the brain following intranasal administration of SARS-CoV-2, demonstrating the virus's neurotropic characteristics.[12,13] Several mechanisms of neuroinvasion have been proposed.

SARS-CoV-2 may directly infect vascular endothelial cells, potentially allowing the virus to cross the blood-brain barrier (BBB).[14] Another entry route to the central nervous system (CNS) may involve the olfactory nerve, where the virus can travel from the nasal passages to the brain.[15] Damage to lung blood vessels can lead to viral entry into the bloodstream, facilitating spread to other organs, including the brain.[16] Additionally, SARS-CoV-2 can induce systemic inflammatory responses, which have the potential to disrupt the BBB and permit the virus or infected immune cells to reach the brain.[17] Furthermore, SARS-CoV-2 may utilize certain entry proteins

expressed in the brain, such as ACE2, NRP1, and BSG, to facilitate its invasion.[18]

To address this growing concern, strategies for early detection and intervention are vital. Early detection involves monitoring COVID-19 patients for neurological symptoms like anosmia or ageusia.[19,20] Using brain organoids and in vivo models can help simulate and study the neuroinvasive potential of the virus.[21] For early intervention, research efforts should focus on potential treatments that block the pathways SARS-CoV-2 uses to invade the CNS. Exploring treatments that reduce inflammation or restore the integrity of the BBB is crucial to prevent SARS-CoV-2 entry into the brain.[22,23] The efficacy of brain-penetrant antiviral drugs like Sofosbuvir in treating SARS-CoV-2 CNS infection should be investigated.[24] Further study of ACE2, NRP1, and other receptors in the human brain is essential for developing targeted interventions.[25]



Figure 2. Evidence of SARS-CoV-2 Invasion in Autopsy Samples. Autopsy Analysis of (a) CoV antigen detected by anti-SARS-CoV protein antibodies (brown), (b) SARS-CoV-2 RNA ISH showing intense signals in the mucus layer and cells (arrows) of the epithelium, (c-f), Ultrastructural images of CoV-particles (c, arrows) attached to kinocilia (c, white asterisks) and intracellular CoV particles (d-f), (f) high magnification of CoV particles (black arrows).



Figure 3. Potential Pathophysiological Mechanisms Underlying Cerebral Vascular Involvement in COVID-19. A schematic representation of hypothesized mechanisms linking COVID-19 to cerebral vascular damage, focusing on endothelial injury, coagulopathy, and inflammation contributing to neurological manifestations.

4. Neuroprotective Strategies for Managing Neurological Damage

Neurological damage mitigation is a complex and multifaceted endeavor, necessitating a comprehensive approach that delves into diverse strategies aimed at minimizing harm to the delicate nervous system. Among these crucial strategies, three stand out prominently: the utilization of anti-inflammatory drugs, the deployment of antiviral agents, and the preservation of the blood-brain barrier

5. Strategies for Neurological Damage Mitigation

In the realm of neuroprotection, the role of anti-inflammatory drugs is paramount, functioning as key players in the effort to minimize neuronal damage. These drugs operate with precision by targeting the reduction of inflammation, a critical factor in the pathophysiology of various neurological complications. Specifically, their primary objective is to down-regulate proinflammatory cytokines such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α).[26] This targeted approach aims to

mitigate the severity of associated complications, emphasizing the importance of managing inflammatory responses in the intricate landscape of neurological health.

Another pivotal strategy in the arsenal against neurological challenges involves the use of antiviral agents. These agents act as guardians by inhibiting viral activity, a crucial aspect in the preservation of neurological well-being. Their mechanisms extend beyond mere suppression, encompassing the impediment of virus entry into the central nervous system and the downregulation of virus receptors. By curbing viral activity, these agents make significant strides in reducing neurotoxicity, fortifying the defense against potential neurological damage.

The preservation of the blood-brain barrier emerges as a linchpin in the safeguarding of neurological integrity. Functioning as a protective barricade, this barrier regulates the passage of substances between the bloodstream and the brain. The maintenance of this barrier is not only fundamental but also integral in preventing neurological damage. A breach in this defense could potentially expose the delicate neural environment to harmful agents, emphasizing the critical role of a robust blood-brain barrier in neurological health.

Within this intricate landscape, the exploration of Histone Deacetylase Inhibitors (HDACi) emerges as a significant avenue.[27] HDACi holds promise in the amelioration of neurological damage through a multifaceted approach. These inhibitors demonstrate efficacy by down-regulating proinflammatory cytokines, thereby curbing the inflammatory response. Additionally, HDACi plays a pivotal role in impeding virus entry and replication within the central nervous system, adding another layer of defense against potential neurological threats.

6. Ongoing Research and Clinical Trials for Novel Therapeutic Solutions

The ongoing pursuit of effective interventions for managing and mitigating neurological damage caused by viral infections is a dynamic field that

continually expands through comprehensive clinical trials. These trials encompass a diverse array of therapeutic options, ranging from traditional pharmaceutical interventions to cutting-edge approaches like cell therapy. In-depth exploration into convalescent plasma therapy, monoclonal antibodies, immunoglobulin therapy, and cell therapy provides a nuanced understanding of their potential efficacy in addressing neurological complications arising from viral infections.[28]

Out of the ongoing clinical initiatives, approximately 86% focus on examining the efficacy of small molecules or antibodies, either in isolation or in conjunction with immunomodulators. The remaining approximately 14% of clinical endeavors are directed towards assessing vaccines and therapies based on convalescent plasma to alleviate symptoms associated with the disease.[29]

Vaccination, as a proactive measure against the spread of viruses with neurological implications, remains a crucial focus. Emerging technologies, such as nanoparticle vaccines, present a promising avenue. These vaccines, designed to combine spike proteins from multiple coronaviruses, hold the potential to offer broad protection against diverse strains. The exploration of these innovative vaccination strategies adds a layer of anticipation to the ongoing efforts in preventing and minimizing neurological complications associated with viral infections.[30]

Furthermore, investigations into prominent drugs and therapies broaden the spectrum of our understanding. Protease inhibitors, RNA-dependent RNA polymerase inhibitors, immunomodulatory treatments, and gene-editing techniques like CRISPR represent the frontier of antiviral research.[31] By targeting various aspects of viral infections, these interventions aim to disrupt the replication and progression of viruses within the body. A comprehensive grasp of the specifics of these trials, including the drugs investigated and the precise aspects of viral infections they address, enhances our comprehension and sets the stage for potential breakthroughs in neuroprotection.

7. Impact on Patient Care and Healthcare Systems

The exploration and application of prospective therapies hold immense promise in significantly elevating the standard of patient care, presenting a diversified arsenal of treatment options and preventive measures. The direct targeting of neurological impacts stemming from viral infections through these therapies marks a crucial advancement in the medical landscape. However, a comprehensive understanding of the challenges that may arise during the implementation of these interventions is imperative for a nuanced approach to patient care enhancement.

Effective therapies not only promise to ameliorate the specific neurological complications associated with viral infections but also have the potential to address broader healthcare challenges. By reducing the severity and incidence of these complications, these interventions could alleviate the burden on healthcare systems. This, in turn, paves the way for more efficient and streamlined patient care, fostering an environment where resources are optimized, and healthcare professionals can focus on delivering comprehensive and timely treatments.[32]

The public health implications of incorporating prospective therapies into the broader healthcare framework are profound. The necessity of widespread vaccination campaigns takes center stage, emphasizing the importance of preventing the spread of viruses, particularly SARS-CoV-2, which has demonstrated significant impacts on neurological health. Concurrently, the establishment of early detection protocols emerges as a critical strategy in mitigating the overall impact on public health.[33]

Addressing the challenges associated with implementing these therapies becomes a focal point for healthcare systems aiming to optimize patient care. By proactively tackling barriers to access, affordability, and dissemination of these prospective therapies, healthcare systems can better navigate the complexities of neurological health management. This holistic approach not only benefits individual patients affected by viral infections but also contributes to the overall resilience and adaptability of healthcare infrastructures.[34]

8. Conclusion

Navigating the Complex Terrain of SARS-CoV-2 Neurological Impact

In the wake of the COVID-19 Pandemic, this comprehensive review has ventured into the intricate landscape of neuroinvasive infections, focusing on the unprecedented global impact and neurological consequences of the SARS-CoV-2 pathogen. From exploring the multifaceted world of neuroinvasion mechanisms to unraveling the evidence of neurological damage, this journey has aimed to shed light on the complexities that define the interplay between pathogens and the nervous system.

The significance of SARS-CoV-2's global impact becomes increasingly apparent as we navigate the neurological spectrum it presents, from mild symptoms to severe conditions. The virus's ability to infiltrate the central nervous system adds layers of complexity to the ongoing battle against its repercussions, urging researchers and clinicians to adapt and devise effective therapeutic strategies.[35]

This review has highlighted the importance of robust therapeutic interventions that address the diverse manifestations of neurological damage caused by SARS-CoV-2. Strategies for early detection and intervention have been highlighted as key components in mitigating the severity of neurological consequences, The evidence of neuroinvasion, gleaned from autopsy analyses, human brain organoids, and in vivo studies, forms a foundation for future research directions and targeted interventions.

As we navigate the intricate terrain of SARS-CoV-2's impact on the nervous system, the pursuit of effective therapeutic solutions is emphasized. Ongoing research and clinical trials offer hope to explore novel approaches ranging from traditional pharmaceutical methods to cutting-edge techniques, like cell therapy. The dynamic field of neuroprotection continues to expand, providing a nuanced understanding of potential breakthroughs in managing and mitigating neurological damage caused by viral infections.

As we stand at the intersection of scientific inquiry and practical application, this review propels us forward into a future where adaptability, resilience, and comprehensive understanding pave the way for advancements in neuroinvasive pathogenic research. The journey to unravel the mysteries of SARS-CoV-2 continues and will be guided by the collective efforts of the scientific community in the pursuit of relief and hope for those affected by the consequences of COVID-19.

References

1. Sips GJ, Wilschut J, Smith JM. Neuroinvasive flavivirus infections. *Rev Med Virol.* 2011;21(2):69-87. doi:10.1002/rmv.712.

2. Davis LE, Lyons JL. Acute neurological infections. *Medicine (Baltimore).* Published July 25, 2020. Accessed October 27, 2023. https://www.sciencedirect.com/science/article/pii/S1357303920301419.

3. Davis LE, Lyons JL. Acute neurological infections. *Medicine (Baltimore).* Published July 25, 2020. Accessed October 27, 2023. https://www.sciencedirect.com/science/article/pii/S1357303920301419.

4. Uddin F, Rudin CM, Sen T. CRISPR gene therapy: Applications, limitations, and implications for the future. *Front Oncol.* 2020;10:1387. doi:10.3389/fonc.2020.01387.

5. Desforges M, Coupanec AL, Dubeau P, et al. Human coronaviruses and other respiratory viruses: Underestimated opportunistic pathogens of the central nervous system? *Viruses.* 2019;11(1):59. doi:10.3390/v11010059.

6. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci.* 2021;24(2):168-175. doi:10.1038/s41593-020-00758-5.

7. Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). *J Med Virol.* 2020;92(7):699-702. doi:10.1002/jmv.25915.

8. Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. *JAMA Neurol.* 2020;77(8):1028-1029. doi:10.1001/jamaneurol.2020.2125.

9. Tsivgoulis G, Palaiodimou L, Zand R, et al. COVID-19 and cerebrovascular diseases: A comprehensive overview. *Ther Adv Neurol Disord.* 2020;13:1756286420978004. doi:10.1177/1756286420978004.

10. Jacob JT, Baker JM, Fridkin SK, et al. Risk factors associated with SARS-CoV-2 seropositivity among US healthcare personnel. *JAMA Netw Open.* 2021;4(3):e211283. doi:10.1001/jamanetworkopen.2021.1283.

11. Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J Exp Med.* 2021;218(3):e20202135. doi:10.1084/jem.20202135.

12. McCray PB Jr, Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. *J Virol.* 2007;81(2):813-821. doi:10.1128/JVI.02012-06.

13. Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J Exp Med.* 2021;218(3):e20202135. doi:10.1084/jem.20202135.

14. Reichard RR, Kashani KB, Boire NA, et al. Neuropathology of COVID-19: A spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. *Acta Neuropathol.* 2020;140(1):1-6.

doi:10.1007/s00401-020-02166-2.

15. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci.* 2021;24(2):168-175. doi:10.1038/s41593-020-00758-5.

16. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet.* 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5.

17. Kantonen J, Mahzabin S, Mäyränpää MI, et al. Neuropathologic features of four autopsied COVID-19 patients. *Brain Pathol.* 2020;30(6):1012-1016. doi:10.1111/bpa.12889.

18. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science.* 2020;367(6485):1444-1448. doi:10.1126/science.abb2762.

19. Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. *JAMA Neurol.* 2020;77(8):1028-1029. doi:10.1001/jamaneurol.2020.2125.

20. Tsivgoulis G, Palaiodimou L, Zand R, et al. COVID-19 and cerebrovascular diseases: A comprehensive overview. *Ther Adv Neurol Disord.* 2020;13:1756286420978004. doi:10.1177/1756286420978004.

21. Jacob JT, Baker JM, Fridkin SK, et al. Risk factors associated with SARS-CoV-2 seropositivity among US healthcare personnel. *JAMA Netw Open.* 2021;4(3):e211283. doi:10.1001/jamanetworkopen.2021.1283.

22. Reichard RR, Kashani KB, Boire NA, et al. Neuropathology of COVID-19: A spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. *Acta Neuropathol.* 2020;140(1):1-6. doi:10.1007/s00401-020-02166-2.

23. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet.* 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5.

24. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci.* 2021;24(2):168-175. doi:10.1038/s41593-020-00758-5.

25. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science.* 2020;367(6485):1444-1448. doi:10.1126/science.abb2762.

26. Malik S, Gupta A, Zhong X, et al. Emerging therapeutic modalities against COVID-19. *Pharmaceuticals.* 2020;13(8):221. doi:10.3390/ph13080221.

27. Niknam Z, Jafari A, Golchin A, et al. Potential therapeutic options for COVID-19: An update on current evidence. *Eur J Med Res.* 2022;27(1):6. doi:10.1186/s40001-021-00626-3.

28. Niknam Z, Jafari A, Golchin A, et al. Potential therapeutic options for COVID-19: An update on current evidence. *Eur J Med Res.*

2022;27(1):6. doi:10.1186/s40001-021-00626-3.

29. Malik S, Gupta A, Zhong X, et al. Emerging therapeutic modalities against COVID-19. *Pharmaceuticals.* 2020;13(8):221. doi:10.3390/ph13080221.

30. Malik S, Gupta A, Zhong X, et al. Emerging therapeutic modalities against COVID-19. *Pharmaceuticals.* 2020;13(8):221. doi:10.3390/ph13080221.

31. Uddin F, Rudin CM, Sen T. CRISPR gene therapy: Applications, limitations, and implications for the future. *Front Oncol.* 2020;10:1387. doi:10.3389/fonc.2020.01387.

32. Malik S, Gupta A, Zhong X, et al. Emerging therapeutic modalities against COVID-19. *Pharmaceuticals.* 2020;13(8):221. doi:10.3390/ph13080221.

33. U.S. Department of Health and Human Services. Research in context: Progress toward universal vaccines. *NIH News Events.* Published August 8, 2023. https://www.nih.gov/news-events/nih-research-matters/research-context-progress-toward-universal-vaccines.

34. U.S. Department of Health and Human Services. Research in context: Progress toward universal vaccines. *NIH News Events.* Published August 8, 2023. https://www.nih.gov/news-events/nih-research-matters/research-context-progress-toward-universal-vaccines.

35. Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J Exp Med.* 2021;218(3):e20202135. doi:10.1084/jem.20202135.